Progress or lack of progress in hospitalized heart failure

References

• Gheorghiade M, Shah AN, Vaduganathan M et al. Recognizing Hospitalized Heart Failure as an Entity and Developing New Therapies to Improve Outcomes: Academics’, Clinicians’, Industry's, Regulators’, and Payers’ Perspectives. Heart Fail. Clin. 9(3), 285–290 (2013).
   PubMed Web of Science ®Google Scholar
• Go AS, Mozaffarian D, Roger VL et al. Executive summary: heart disease and stroke statistics–2013 update: a report from the American Heart Association. Circulation 127(1), 143–152 (2013).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Bohm M, Greene SJ et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 309(11), 1125–1135 (2013).
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Stough WG, Abraham WT et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: a report from the OPTIMIZE-HF Registry. J. Am. Coll. Cardiol. 50(8), 768–777 (2007).
   PubMed Web of Science ®Google Scholar
• Chen J, Dharmarajan K, Wang Y, Krumholz HM. National trends in heart failure hospital stay rates, 2001 to 2009. J. Am. Coll. Cardiol. 61(10), 1078–1088 (2013).
   PubMed Web of Science ®Google Scholar
• Blair JE, Zannad F, Konstam MA et al. Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. J. Am. Coll. Cardiol. 61(20), 1640–1648 (2008).
   Google Scholar
• Butler J, Subacius H, Vaduganathan M et al. Relationship between clinical trial site enrollment with participant characteristics, protocol completion, and outcomes: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial. J. Am. Coll. Cardiol. 61(5), 571–579 (2013).
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Adams KF Jr., Abraham WT et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis. JAMA 293(5), 572–580 (2005).
   PubMed Web of Science ®Google Scholar
• O'Connor CM, Abraham WT, Albert NM et al. Predictors of mortality after discharge in patients hospitalized with heart failure: an analysis from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). Am. Heart J. 61(4), 662–673 (2008).
   Google Scholar
• Gheorghiade M, Abraham WT, Albert NM et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: an analysis from the OPTIMIZE-HF registry. Eur. Heart J. 61(8), 980–988 (2007).
   Google Scholar
• Gheorghiade M, Konstam MA, Burnett JC Jr et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 297(12), 1332–1343 (2007).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Abraham WT, Albert NM et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296(18), 2217–2226 (2006).
   PubMed Web of Science ®Google Scholar
• Blair JE, Pang PS, Schrier RW et al. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. Eur. Heart J. 61(20), 2563–2572 (2011).
   Google Scholar
• Wang NC, Maggioni AP, Konstam MA et al. Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA 299(22), 2656–2666 (2008).
   PubMed Web of Science ®Google Scholar
• Mentz RJ, Allen BD, Kwasny MJ et al. Influence of documented history of coronary artery disease on outcomes in patients admitted for worsening heart failure with reduced ejection fraction in the EVEREST trial. Eur. J. Heart Fail. 61(1), 61–68 (2013).
   Google Scholar
• Mentz RJ, Schmidt PH, Kwasny MJ et al. The impact of chronic obstructive pulmonary disease in patients hospitalized for worsening heart failure with reduced ejection fraction: an analysis of the EVEREST Trial. J. Card. Fail. 61(7), 515–523 (2012).
   Google Scholar
• Mebazaa A, Pang PS, Tavares M et al. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur. Heart J. 61(7), 832–841 (2010).
   Google Scholar
• Gheorghiade M, Zannad F, Sopko G et al. Acute heart failure syndromes: current state and framework for future research. Circulation 112(25), 3958–3968 (2005).
   PubMed Web of Science ®Google Scholar
• Felker GM, Lee KL, Bull DA et al. Diuretic strategies in patients with acute decompensated heart failure. N. Engl. J. Med. 61(9), 797–805 (2011).
   Google Scholar
• Bart BA, Goldsmith SR, Lee KL et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N. Engl. J. Med. 61(24), 2296–2304 (2012).
   Google Scholar
• Cuffe MS, Califf RM, Adams KF Jr et al. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 287(12), 1541–1547 (2002).
   PubMed Web of Science ®Google Scholar
• Elkayam U, Tasissa G, Binanay C et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am. Heart J. 61(1), 98–104 (2007).
   Google Scholar
• Abraham WT, Adams KF, Fonarow GC et al. In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J. Am. Coll. Cardiol. 61(1), 57–64 (2005).
   Google Scholar
• Metra M, Eichhorn E, Abraham WT et al. Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials. Eur. Heart J. 61(24), 3015–3026 (2009).
   Google Scholar
• Felker GM, Benza RL, Chandler AB et al. Heart failure etiology and response to milrinone in decompensated heart failure: results from the OPTIME-CHF study. J. Am. Coll. Cardiol. 61(6), 997–1003 (2003).
   Google Scholar
• Fonarow GC, Heywood JT, Heidenreich PA et al. Temporal trends in clinical characteristics, treatments, and outcomes for heart failure hospitalizations, 2002 to 2004: findings from Acute Decompensated Heart Failure National Registry (ADHERE). Am. Heart J. 61(6), 1021–1028 (2007).
   Google Scholar
• Fonarow GC, Abraham WT, Albert NM et al. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA 297(1), 61–70 (2007).
   PubMed Web of Science ®Google Scholar
• Fonarow GC, Abraham WT, Albert NM et al. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J. Am. Coll. Cardiol. 61(3), 190–199 (2008).
   Google Scholar
• Fonarow GC, Abraham WT, Albert NM et al. Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: results of the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (OPTIMIZE-HF). Arch. Int. Med. 167(14), 1493–1502 (2007).
   Google Scholar
• Pitt B, Remme W, Zannad F et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 61(14), 1309–1321 (2003).
   Google Scholar
• Pitt B, Kober L, Ponikowski P et al. Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94–8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur. Heart J. (2013).
   Web of Science ®Google Scholar
• Gheorghiade M, Patel K, Filippatos G et al. Effect of oral digoxin in high-risk heart failure patients: a pre-specified subgroup analysis of the DIG trial. Eur. J. Heart Fail. 61(5), 551–559 (2013).
   Google Scholar
• Bourge RC, Fleg JL, Fonarow GC et al. Digoxin Reduces 30-day All-cause Hospital Admission in Older Patients with Chronic Systolic Heart Failure. Am. J. Med. (2013).
   Google Scholar
• O'Connor CM, Starling RC, Hernandez AF et al. Effect of nesiritide in patients with acute decompensated heart failure. N. Engl. J. Med. 61(1), 32–43 (2011).
   Google Scholar
• Massie BM, O'Connor CM, Metra M et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N. Engl. J. Med. 61(15), 1419–1428 (2010).
   Google Scholar
• Packer M, Colucci W, Fisher L et al. Effect of levosimedan on short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail. 1(2), 103–111 (2013).
   Google Scholar
• Mebazaa A, Nieminen MS, Packer M et al. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 297(17), 1883–1891 (2007).
   PubMed Web of Science ®Google Scholar
• Konstam MA, Gheorghiade M, Burnett JC, Jr et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 297(12), 1319–1331 (2007).
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Greene SJ, Filippatos G et al. Cinaciguat, a soluble guanylate cyclase activator: results from the randomized, controlled, phase IIb COMPOSE programme in acute heart failure syndromes. Eur. J. Heart Fail. 61(9), 1056–1066 (2012).
   Google Scholar
• Gheorghiade M, Marti CN, Sabbah HN et al. Soluble guanylate cyclase: a potential therapeutic target for heart failure. Heart Fail. Rev. 61(2), 123–134 (2013).
   Google Scholar
• Teerlink JR, Cotter G, Davison BA et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381(9860), 29–39 (2013).
   PubMed Web of Science ®Google Scholar
• Swedberg K, Komajda M, Bohm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 376(9744), 875–885 (2010).
   PubMed Web of Science ®Google Scholar